检测 hsCRP——全面风险评估的重要组成部分，还是临床上多余的做法？
Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice?
机构信息
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
出版信息
PLoS Med. 2010 Feb 2;7(2):e1000196. doi: 10.1371/journal.pmed.1000196.
Abstract
James McCormack and Michael Allan discuss issues and questions surrounding hsCRP measurements in patients.
摘要
詹姆斯·麦考马克和迈克尔·艾伦讨论了有关 hsCRP 测量在患者中的问题。
相似文献
1
Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice?检测 hsCRP——全面风险评估的重要组成部分，还是临床上多余的做法？
PLoS Med. 2010 Feb 2;7(2):e1000196. doi: 10.1371/journal.pmed.1000196.
2
Is hsCRP Back on Board? Implications from the JUPITER Trial.超敏C反应蛋白又回来了？来自JUPITER试验的启示。
Clin Chem. 2009 Feb;55(2):216-8. doi: 10.1373/clinchem.2008.115915. Epub 2008 Dec 12.
3
Jupiter to Earth: CRP promotes atherothrombosis.《自然》子刊：C反应蛋白促进动脉粥样硬化血栓形成
Metab Syndr Relat Disord. 2009 Feb;7(1):1-3. doi: 10.1089/met.2009.EDI.
4
The Jupiter trial: key findings, controversies, and implications.“朱庇特”试验：主要发现、争议及影响
Curr Cardiol Rep. 2009 Mar;11(2):81-2. doi: 10.1007/s11886-009-0013-0.
5
[Comment from the cardiologic viewpoint].[心脏病学视角的评论]
Praxis (Bern 1994). 2009 Feb 4;98(3):129-30. doi: 10.1024/1661-8157.98.3.129.
6
The Post-JUPITER trial era and the cost of preventive medicine.JUPITER试验后的时代与预防医学的成本
Hellenic J Cardiol. 2010 Mar-Apr;51(2):187-8.
7
Rosuvastatin in patients with elevated C-reactive protein.瑞舒伐他汀用于C反应蛋白升高的患者。
N Engl J Med. 2009 Mar 5;360(10):1040; author reply 1041-2.
8
JUPITER study highlights value of anti-inflammatory action of rosuvastatin.JUPITER研究突出了瑞舒伐他汀抗炎作用的价值。
Cardiovasc J Afr. 2009 May-Jun;20(3):211.
9
Use of high-sensitivity CRP to predict first cardiovascular events.使用高敏C反应蛋白预测首次心血管事件。
Lancet. 2007 Apr 14;369(9569):1259-1260. doi: 10.1016/S0140-6736(07)60594-7.
10
JUPITER clinical directions--polling results.JUPITER临床指南——民意调查结果
N Engl J Med. 2009 Mar 5;360(10):e14. doi: 10.1056/NEJMe086509.
引用本文的文献
1
Differential Associations of Cigar, Pipe, and Smokeless Tobacco Use Versus Combustible Cigarette Use With Subclinical Markers of Inflammation, Thrombosis, and Atherosclerosis: The Cross-Cohort Collaboration-Tobacco Working Group.雪茄、烟斗和无烟烟草使用与可燃香烟使用与炎症、血栓形成和动脉粥样硬化亚临床标志物的差异关联：跨队列合作-烟草工作组
Circulation. 2025 Apr 8;151(14):993-1005. doi: 10.1161/CIRCULATIONAHA.124.070852. Epub 2025 Jan 27.
2
Salivary High-Sensitivity C-Reactive Protein and Its Clinical Relevance in Modern Medicine: A Comprehensive Review.唾液高敏C反应蛋白及其在现代医学中的临床意义：综述
Cureus. 2024 Apr 13;16(4):e58165. doi: 10.7759/cureus.58165. eCollection 2024 Apr.
3
Association between active commuting and low-grade inflammation: a population-based cross-sectional study.主动通勤与低度炎症之间的关联：基于人群的横断面研究。
Eur J Public Health. 2024 Apr 3;34(2):292-298. doi: 10.1093/eurpub/ckad213.
4
C-reactive protein and fracture risk: an updated systematic review and meta-analysis of cohort studies through the use of both frequentist and Bayesian approaches.C 反应蛋白与骨折风险：基于经典和贝叶斯两种方法的系统回顾和队列研究荟萃分析的更新
Osteoporos Int. 2021 Mar;32(3):425-435. doi: 10.1007/s00198-020-05623-6. Epub 2020 Sep 15.
5
Atherosclerosis in systemic lupus erythematosus.系统性红斑狼疮中的动脉粥样硬化。
J Cardiovasc Pharmacol. 2013 Sep;62(3):255-62. doi: 10.1097/FJC.0b013e31829dd857.
6
The effects of pre- and post-exercise consumption of multi-ingredient performance supplements on cardiovascular health and body fat in trained men after six weeks of resistance training: a stratified, randomized, double-blind study.经过六周抗阻训练后，运动前和运动后摄入多成分性能补充剂对男性受训者心血管健康和体脂的影响：一项分层、随机、双盲研究。
Nutr Metab (Lond). 2013 May 16;10(1):39. doi: 10.1186/1743-7075-10-39.
7
Prognostic utility of biochemical markers of cardiovascular risk: impact of biological variability.心血管风险生化标志物的预后价值：生物学变异性的影响。
Clin Chem Lab Med. 2013 Sep;51(9):1875-82. doi: 10.1515/cclm-2012-0750.
8
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.在ARIES研究中，未接受过抗逆转录病毒治疗的HIV感染患者接受阿巴卡韦/拉米夫定/阿扎那韦联合或不联合利托那韦治疗144周后炎症生物标志物的变化及其与弗雷明汉姆心血管风险和血脂变化的相关性。
AIDS Res Hum Retroviruses. 2013 Feb;29(2):350-8. doi: 10.1089/aid.2012.0278. Epub 2012 Dec 5.
9
Practical use of the Framingham risk score in primary prevention: Canadian perspective.弗雷明汉风险评分在初级预防中的实际应用：加拿大视角。
Can Fam Physician. 2011 Apr;57(4):417-23.
本文引用的文献
1
C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study.弗雷明汉心脏研究中C反应蛋白与心血管风险重新分类
Circ Cardiovasc Qual Outcomes. 2008 Nov;1(2):92-7. doi: 10.1161/CIRCOUTCOMES.108.831198. Epub 2008 Nov 9.
2
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.瑞舒伐他汀起始治疗后C反应蛋白、低密度脂蛋白胆固醇降低及心血管事件发生率：JUPITER试验的前瞻性研究
Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.
3
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.瑞舒伐他汀预防C反应蛋白升高的男性和女性发生血管事件。
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
4
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.C反应蛋白和家族病史可改善总体心血管风险预测：男性的雷诺兹风险评分
Circulation. 2008 Nov 25;118(22):2243-51, 4p following 2251. doi: 10.1161/CIRCULATIONAHA.108.814251. Epub 2008 Nov 9.
5
Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts.对用于预测冠心病事件的C反应蛋白测量的批判性评价：新数据及对31个前瞻性队列的系统评价
Int J Epidemiol. 2009 Feb;38(1):217-31. doi: 10.1093/ije/dyn217. Epub 2008 Oct 17.
6
Simvastatin with or without ezetimibe in familial hypercholesterolemia.辛伐他汀联合或不联合依折麦布治疗家族性高胆固醇血症
N Engl J Med. 2008 Apr 3;358(14):1431-43. doi: 10.1056/NEJMoa0800742. Epub 2008 Mar 30.
7
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.他汀类药物14项随机试验中18686例糖尿病患者降脂治疗的疗效：一项荟萃分析。
Lancet. 2008 Jan 12;371(9607):117-25. doi: 10.1016/S0140-6736(08)60104-X.
8
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.罗格列酮与心血管事件的长期风险：一项荟萃分析。
JAMA. 2007 Sep 12;298(10):1189-95. doi: 10.1001/jama.298.10.1189.
9
Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.抗氧化剂补充剂用于一级和二级预防的随机试验中的死亡率：系统评价和荟萃分析。
JAMA. 2007 Feb 28;297(8):842-57. doi: 10.1001/jama.297.8.842.
10
Multiple biomarkers for the prediction of first major cardiovascular events and death.用于预测首次重大心血管事件和死亡的多种生物标志物。
N Engl J Med. 2006 Dec 21;355(25):2631-9. doi: 10.1056/NEJMoa055373.
Zotero 插件